Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Key facts
- Who runs it
- The University of Hong Kong
- Where
- Hong Kong, Hong KongSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 180 people, planned
- Started
- 26 Sept 2023
- Expected to end
- 31 Mar 2027
- Type of study
- Observational
- Treatments tested
- Continuous Positive Airway Pressure or other management for OSA per clinical indications.
- Record updated
- 2 April 2025
Who can take part
- Age
- 50 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Aged 50 - 80 years
- Diagnosis of mild cognitive impairment based on Peterson's criteria
- Diagnosis of subjective cognitive impairment, based on the subjective complaint of cognitive impairment, but with an unremarkable assessment of the Hong Kong version of Montreal cognitive Assessment scores
- Able to speak and read Chinese
- Adequate visual and auditory to perform a cognitive test
- Subjects with moderate-severe OSA or No OSA (diagnosis based on sleep study) would be invited for baseline PET-MRI brain scan
Who cannot take part
- Diagnosed psychiatric illness with or without medication, e.g. major depressive disorder
- Other clear organic causes of cognitive impairment, e.g. vascular cognitive impairment, brain tumour, dementia with Lewy body, mild cognitive impairment with Lewy body, Parkinson's disease, normal pressure hydrocephalus, neurosyphilis, autoimmune encephalitis, substance abuse, history of alcohol abuse
- Diagnosis of cancer on active treatment
- Contraindications to PET-CT or MRI brain scan (excluded for neuroimaging studies)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Where in Hong Kong
- Queen Mary HospitalHong Kong, Hong KongContact: Sau Man Mary Ip, MDTaking people
About the trial
What the trial wants to find out
Obstructive sleep apnea (OSA) is recurrent episodes of partial or complete obstruction of the upper airway during sleep that causes intermittent hypoxia and sleep fragmentation and potentially lead to cardiometabolic and neurocognitive sequelae. Chronic intermittent hypoxia, sleep fragmentation of OSA, and insufficient sleep have been significantly associated with higher risks of neurocognitive impairment, including mild cognitive impairment (MCI) and Alzheimer's disease. Thus, sleep and sleep apnea might be modifiable factors to neurocognitive impairment.
Read full original descriptionShow less
Positive airway pressure (PAP) is the first line of treatment to maintain open airways for patients with OSA. Improving sleep, sleep apnea and circadian function could be a high-value intervention target to alleviate cognitive impairment and decline in subjects with mild neurocognitive impairment.
Amyloid accumulation in brain tissue is a distinct feature of Alzheimers' disease, which is associated with potential impairment of neurocognition clinically. It predicts memory decline in initially cognitively unimpaired individuals.
The study explores the associations between sleep apnea, cognitive function and cerebral imaging and the role of PAP therapy on neurocognitive trajectory in these patients with subjective cognitive impairment /mild cognitive impairment (SCI/MCI).
The group in the trial
- Subjective or mild cognitive impairment patients
Subjective or mild cognitive impairment patients with or without CPAP treatment
Treatment: Continuous Positive Airway Pressure or other management for OSA per clinical indications.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Exploring the Association Between Cognitive Function, Obstructive Sleep Apnea and Brain Imaging, and the Determinants of Neurocognitive Decline in Subjects With Subjective or Mild Cognitive Impairment
- Fit questions
- Built from NCT06150352, who can take part
- Record updated
- 2 April 2025